Preclinical Research
Tonix Pharmaceuticals Presents Preclinical Immuno-Oncology Data at AACR 2026, Highlighting Potential in Gastric Cancer and Immunotherapy
Tonix Pharmaceuticals announced new preclinical data for TNX-1700 and TNX-4700 at AACR 2026, showing potential in gastric cancer and as a BTLA-targeting immunotherapy, which could expand its oncology pipeline.
Tevard Biosciences Demonstrates Breakthrough Protein Restoration in Genetic Muscle and Heart Diseases
Tevard Biosciences presented preclinical data showing its tRNA-based therapy can restore 70% of functional proteins in Duchenne muscular dystrophy and dilated cardiomyopathy models, potentially enabling clinical advancement for genetic diseases affecting millions worldwide.
Tonix Pharmaceuticals to Showcase TNX-801 Mpox Vaccine Data at Vaccine Congress 2025
Tonix Pharmaceuticals will present preclinical data on its TNX-801 mpox vaccine candidate at the Vaccine Congress 2025, highlighting its potential to address public health threats.
InMed Pharmaceuticals Reports Promising Preclinical Results for Alzheimer's Treatment
InMed Pharmaceuticals Inc. announces positive preclinical results for INM-901, showing potential in reducing neuroinflammation associated with Alzheimer's disease, independent of amyloid beta or tau pathology.
Telomir Pharmaceuticals Reports Preclinical Success for Telomir-1 in Progeria Cell Lines
Telomir Pharmaceuticals' preclinical data shows Telomir-1's potential in preventing cellular aging in progeria cell lines, marking a significant advancement in treating Hutchinson-Gilford Progeria Syndrome (HGPS).
Telomir Pharmaceuticals Reports Significant Preclinical Breakthrough with Telomir-1 in Wilson’s Disease Model
Telomir Pharmaceuticals' preclinical data reveals Telomir-1's potential to reverse symptoms of Wilson’s disease, a rare copper accumulation disorder, marking a significant step towards human trials and offering hope for patients.
Lifordi Immunotherapeutics Unveils Promising Preclinical Data for LFD-200 at EULAR 2025
Lifordi Immunotherapeutics has presented preclinical data on LFD-200, a novel antibody-drug conjugate targeting autoimmune and inflammatory diseases, showing efficacy without systemic toxicity, marking a potential breakthrough in treatment options.
Kairos Pharma Ltd. Showcases Promising Preclinical Results for KROS101 at ASCO 2025
Kairos Pharma Ltd. reveals preclinical data at ASCO 2025 indicating KROS101's potential to enhance cancer immunotherapy by improving T cell activity and reducing immune suppression.
Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700
Tonix Pharmaceuticals presented positive preclinical results for TNX-1700, a fusion protein showing potential in reducing immunosuppressive cells and enhancing anti-tumor immune responses in gastric cancer models, particularly when combined with anti-PD1 therapy.
Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data
Tonix Pharmaceuticals presented preclinical data on TNX-801, a single-dose mpox vaccine that demonstrates robust protection across animal models, potentially offering a significant breakthrough in combating global mpox outbreaks.